PMID- 23797151
OWN - NLM
STAT- MEDLINE
DCOM- 20130925
LR  - 20211203
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 85
IP  - 1
DP  - 2013
TI  - Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who 
      progressed on previous mTOR inhibitor therapy.
PG  - 8-13
LID - 10.1159/000350005 [doi]
AB  - OBJECTIVE: To determine if mammalian target of rapamycin (mTOR) inhibitor 
      (everolimus or temsirolimus) rechallenge in the third- or fourth-line setting 
      after sequential use of a vascular endothelial growth factor receptor 
      (VEGF)-targeted agent and an mTOR inhibitor is a feasible and effective treatment 
      strategy in patients with metastatic renal cell carcinoma (mRCC). METHODS: 
      Patients who received a VEGF-targeted agent, an mTOR inhibitor and rechallenge 
      with a second mTOR inhibitor at 2 institutions (Hopital Europeen Georges-Pompidou 
      and Vienna Medical School) between 30 March 2001 and 15 September 2011 were 
      included. Analyses of radiographic images were performed according to the 
      Response Evaluation Criteria in Solid Tumors, version 1.0, to determine the 
      objective response rate and treatment duration (TD). RESULTS: Twelve patients met 
      the inclusion criteria. Following 1 or 2 VEGF receptor-tyrosine kinase 
      inhibitors, 7 patients firstly received everolimus and 5 patients received 
      temsirolimus. Irrespective of treatment sequence, 6 of 12 patients (50%) 
      responded to everolimus and 4 of 12 patients (33%) responded to temsirolimus; 3 
      patients (25%) did not respond to either. Median TDs (95% confidence interval) 
      for everolimus --> temsirolimus and temsirolimus --> everolimus sequences were 10.3 
      months (8.8-19.2 months) and 5.8 months (2.9-19.3 months), respectively. 
      CONCLUSIONS: Despite the limited number of patients, this highlights the 
      feasibility of utilizing mTOR rechallenge as an integral part of sequential 
      treatment strategies in mRCC.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Maj-Hes, Agnes
AU  - Maj-Hes A
AD  - Department of Urology, Kaiser-Franz-Josef Spital, Vienna, Austria.
FAU - Medioni, Jacques
AU  - Medioni J
FAU - Scotte, Florian
AU  - Scotte F
FAU - Schmidinger, Manuela
AU  - Schmidinger M
FAU - Kramer, Gero
AU  - Kramer G
FAU - Combe, Pierre
AU  - Combe P
FAU - Gornadha, Yohan
AU  - Gornadha Y
FAU - Elaidi, Reza
AU  - Elaidi R
FAU - Oudard, Stephane
AU  - Oudard S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130621
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Protein Kinase Inhibitors)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism/pathology
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Receptors, Vascular Endothelial Growth Factor/metabolism
MH  - Retrospective Studies
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
MH  - Treatment Outcome
EDAT- 2013/06/26 06:00
MHDA- 2013/09/26 06:00
CRDT- 2013/06/26 06:00
PHST- 2013/01/06 00:00 [received]
PHST- 2013/02/13 00:00 [accepted]
PHST- 2013/06/26 06:00 [entrez]
PHST- 2013/06/26 06:00 [pubmed]
PHST- 2013/09/26 06:00 [medline]
AID - 000350005 [pii]
AID - 10.1159/000350005 [doi]
PST - ppublish
SO  - Oncology. 2013;85(1):8-13. doi: 10.1159/000350005. Epub 2013 Jun 21.